Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2006-09-05
2006-09-05
Housel, James (Department: 1648)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S228100, C424S161100, C530S388300
Reexamination Certificate
active
07101551
ABSTRACT:
The present invention provides a substance which inhibits the binding between E2/NS1 protein of hepatitis C virus and a cell infectious with hepatitis C virus, a cell expressing CD81, or CD81. The present invention can provide a novel medicament which has an anti-viral effects such as an inhibitory action against HCV infection.
REFERENCES:
patent: 6692907 (2004-02-01), Weiner et al.
patent: 1181929 (1998-05-01), None
patent: 99/18198 (1999-04-01), None
patent: 00/05266 (2000-02-01), None
patent: 00/26418 (2000-05-01), None
patent: 01/94571 (2001-12-01), None
Pileri, P. “Binding of Hepatitis C Virus to CD81” Science (Oct. 20, 1998) vol. 282, p. 938-941.
Schildbach, J.F. “Contribution of a single heavy chain residue to specificity of an anti-digoxin monoclonal antibody” Prot. Sci. (1994) vol. 3, 737-749.
Winkler, K. “Changing the Antigen Binding Specificity by Single Point Mutations of an Anti-p24 (HIV-1) Antibody” J. Immun. (2000) vol. 165, No. 8, 4505-4514.
Kessler, R.E. “Effects of Subsititution on Polyglycerol Phosphate-Specific Antibody Binding to Lipoteichoic Acids” Infec. Immun. (1983) vol. 41, No. 2, 549-555.
Kussie, P.H. “A Single Engineered Amino Acid Substituiion Changes Antibody Fine Specificity” J. Immun. (1994) vol. 152, No. 1, 146-152; J. Immun. (2000) vol. 165, No. 8, 146-152.
Keck, Z.Y. “Hepatitis C Virsus E2 Has Three Immunogenic Domains Containing Conformational Epitopes with Distinct Properties and Biological Functions” J. Virol. (Sep. 2004) vol. 78, No. 17 9224-9232.
Kabat et al. “Sequence of Proteins of Immunological Interest” Fourth Edition, NIH, pp. vii-xiiv (1987).
Kabat et al. “Sequence of Proteins of Immunological Interest” Fifth Edition, NIH, pp. xii-xcvi, 103-150, and 310-338 (1991).
Yoshiharu Matsuura et al., “Characterization of Pseudotype VSV Possessing HCV Envelope Proteins”, Virology, 286, pp. 263-275 (2001).
Koji Ishii et al., “Structural Analysis of Vaccina Virus Dls Strain: Application as a New Replication-Deficient Viral Vector”, Virology, 302, pp. 433-444 (2002).
Chinese Office Action dated Jun. 3, 2005 (with translation).
K. Masakazu et al., “Antibody response to E2NS1 hepatitis C virus protein in patients with acute hepatitis C”, Journal of Gastroenterology and Hepatology, vol. 12, No. 1, pp. 73-76 (1997).
Qui-Lim Choo et al., “Isolation of a cDNA Clone Derived from a Blood-Borne Non-A, Non-B Viral Hepatitis Genome”,SCIENCE,vol. 244, pp. 259-362 (1989).
Nobuyuki Kato et al., “Molecular Cloning of the Human Hepatitis C Virus Genome from Japanese Patients with non-A, non-B Hepatitis”,Proc. Natl. Acad. Sci. USA,vol. 87, pp. 9524-6528 (1990).
A. Takamizawa et al., “Structure and Organization of the Hepatitis C Virus Genome Isolated from Human Carriers”,Journal of Virology,vol. 65, No. 3, pp. 1105-1113 (1991).
Kunihiko Hino et al., “Genotypes and Titers of Hepatitis C Virus for Predicting Response to Interferon in Patients With Chronic Hepatitis C”,Journal of Medical Virology,vol. 42, pp. 299-305 (1994).
Takeshi Okanoue et al., “Side Effects of Interferon on Endocrine and Repiratory System in 545 Cases of Chronic Hepatitis C”,Journal of Gastroenterology,vol. 91, pp. 995-1002 (1994).
Olle Reichard et al., “Ribavirin Treatment for Chronic Hepatitis C”,The LANCET,vol. 337, pp. 1058-1061 (1991).
Nobuyuki Kato et al., “Humoral Immune Response to Hypervariable Region 1 of the Putative Envelope Glycoprotein (gp70) of Hepatitis C Virus”,Journal of Virology,vol. 67, No. 7, pp. 3922-3930 (1991).
Nobuyuki Kato et al., “Genetic Drift in Hypervariable Region 1 of the Viral Genome in Persistent Hepatitis C Virus Infection”,Journal of Virology,vol. 68, No. 8, pp. 4776-4784 (1994).
Koji Ishii et al., “High Titers of Antibodies Inhibiting the Binding of Envelope to Human Cells Correlate With Natural Resolution of Chronic Hepatitis C”,Hepatology,vol. 28, pp. 1117-1120 (1998).
Piero Pileri et al., “Binding of Hepatitis C Virus to CD81”,SCIENCE,vol. 282, pp. 938-941 (1998).
John Hopwood et al., “Anticoagulant Activity of Heparin: Isolation of Antithrombin-Binding Sites”,FEBS Letters,vol. 69, No. 1, pp. 51-54 (1976).
Avner Yayon et al., “Cell Surface, Heparin-like Moleucles are Required for Binding of Basic Fibroblast Growth Factor to its High Affinity Receptor”,Cell,vol. 64, pp. 841-848 (1991).
Detlef Güssow et al., “Humanization of Monoclonal Antibodies”,Methods in Enzymology,vol. 203, pp. 99-121 (1991).
Frank Lee et al., “Glucocorticoids Regulate Expression of Dihydrofolate Reductase cDNA in Mouse Mammary Tumour Virus Chimaeric Plasmids”,Nature,vol. 294, pp. 228-232 (1981).
Bio Manual Series 4, Gene Introduction and Expression—Analytical Method,pp. 28-35 (1994).
Introductory Antibody Engineering,Chijinshokan Co., Ltd., pp. 20-23.
Shingo Takikaw et al., “Cell Fusion Ativity of Hepatitis C Virus Envelope Protein”,Journal of Virology,vol. 74, No. 11, pp. 5066-5074 (2000).
James D. Marks et al., “By-Passing Immunization: Human Antibodies from V-Gene Libraries Displayed on Phage”,J. Mol. Biol.,vol. 222, pp. 581-597 (1991).
Molecular Cloning,pp. 1.76-1.84 (1982).
Molecular Cloning,pp. 6.46-6.48 (1982).
Tatsurou Shibui et al., “High-Level Production and Secretion of a Mouse-Human Chimeric Fab Fragment with Specificity to Human Carcino Embryonic Antigen inEscherichia Coli”, App. Microbiol Biotechnol,vol. 38, pp. 770-775 (1993).
Yoichiro Aoki et al., “A Human Liver Cell Line Exhibits Efficient Translation of HCV RNAs Produced by a Recombinant Adenovirus Expressing T7 RNA Polymerase”,Virology,vol. 250, pp. 140-150 (1998).
Hide Kikuchi, “Ketsueki Baikai Kansencho HCV”,Rinshou to Kenkyu,vol. 76, No. 7, pp. 1260-1266 (1999).
Tobias Allander et al., “Recombinant Human Monoclonal Antibodies Against Different Conformational Epitopes of the E2 Envelope Glycoprotein of Hepatitis C Virus that Inhibit its Interaction with CD81”,Journal of General Virology,vol. 81, pp. 2451-2459 (2000).
Mike Flint et al., “Functional Analysis of Cell Surface-Expressed Hepatitis C Virus E2 Glycoprotein”,Journal of Virology,vol. 73, No. 8, pp. 6782-6790 (1999).
Mike Flint et al., “Functional Characterization of Intracellular and Secreted Forms of a Truncated Hepatitis C Virus E2 Glycoprotein”,Journal of Virology,vol. 74, No. 2, pp. 702-709 (2000).
Itami Seima
Matsuura Yoshiharu
Miyamura Tatsuo
Seki Makoto
Shibui Tatsurou
Greenblum & Bernstein P.L.C.
Housel James
Japan as Represented by Director General of Agency of National I
Mitsubishi Pharma Corporation
LandOfFree
Remedies for hepatitis C does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Remedies for hepatitis C, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Remedies for hepatitis C will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3607787